Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations - 12/10/21
Doi : 10.1016/j.jaad.2021.08.031
Reid Alexander Waldman, MD a, ⁎ 
, Jane M. Grant-Kels, MD b
, Jane M. Grant-Kels, MD b a Dermatology Associates of Glastonbury, Glastonbury, Connecticut
b Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut
∗Correspondence and reprint requests to: Reid Alexander Waldman, MD, Dermatology Associates of Glastonbury, 210 New London Turnpike, Glastonbury, CT 06132.Dermatology Associates of Glastonbury210 New London TurnpikeGlastonburyCT06132
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : adalimumab, brodalumab, certolizumab, COVID-19, COVID-19 vaccine, dermatology, etanercept, glucocorticoid, golimumab, guselkumab, infliximab, ixekizumab, janus kinase inhibitor, methotrexate, mRNA vaccine, mycophenolate, prednisone, risankizumab, rituximab, SARS-CoV-2, secukinumab, tildrakizumab, vaccine
Abbreviations used : ACIP, mRNA
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
© 2021
Publié par Elsevier Masson SAS.
Vol 85 - N° 5
P. 1113-1116 - novembre 2021 Retour au numéro
Article précédent
- This month in JAAD International: November 2021: COVID-19 and hair loss
- Jonathan Kantor
- First, and foremost, a physician
- Kathryn Schwarzenberger
Bienvenue sur EM-consulte, la référence des professionnels de santé.